Summary: The prevalence of metabolic syndrome (MS) is steadily increasing, with a consequent worsening of patients' cardiovascular prognosis. The most common additional components of MS are atherogenic dyslipidemia and hypertension. Therefore, in daily clinical practice, every effort should be made to first recognize the metabolic syndrome and implement optimal non- -pharmacological and pharmacological therapy. Treatment of dyslipidemia should be based on the use of long-acting and potent statins: atorvastatin and rosuvastatin. In patients who do not reach cholesterol targets, ezetimibe should be added to therapy. In the treatment of hypertension (HT), metabolically neutral groups of hypotensive drugs should be preferred. However, the overarching goal of HT treatment is to achieve its target values. Therefore, one should not be afraid to use diuretics, which are highly effective hypotensives in this group of patients. Moreover, it should be emphasized that only a simultaneous effect on all components of the MS will improve cardiovascular risk.